active underlying SARD warrant more frequent monitoring. Pulmonologists generally see more progressive than long-standing, stable disease and prefer more frequent monitoring. Similarly, the Patient Panel expressed that there is "nothing worse than being missed" and strongly preferred more frequent testing to be reassured that their disease is stable. Because the guideline's target population included people with SARDs who have stable ILD as well as those with progressive ILD, it was important